13F reference period
Q2 2026
Security Snapshot
REGENTIS BIOMATERIALS LTD. - Ordinary Shares, no par value (RGNT) Institutional Ownership
CUSIP: M8211G108
13F Institutional Holders and Ownership History from Q4 2025 to Q2 2026
Institutions Reporting
6
Shares (Excl. Options)
845,791
Price
$3.53
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Shares, no par value
- Symbol
- RGNT on NYSE
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 845,791
- Total 13F value
- $2,984,773
- Portfolio coverage rank
- 0%
- Share change
- +293,947
- Value change
- +$1,179,264
- Number of holders
- 6
- Shares outstanding
- 5,745,116
- SEC-reported price per share
- $1.85
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- RGNT - REGENTIS BIOMATERIALS LTD. - Ordinary Shares, no par value is tracked under CUSIP M8211G108.
- 6 institutions reported positions in Q2 2026.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 3 to 6 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $1,685,883 to $2,984,773.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 6 institutions filings for Q2 2026.
Security key
M8211G108
13F reference period
Q2 2026
13F holders
6
13D/G owners
1
CIK / CUSIP context first
Open Q2 2026 holders
RGNT full holder history
REGENTIS BIOMATERIALS LTD. SEC filings
REGENTIS BIOMATERIALS LTD. company facts
REGENTIS BIOMATERIALS LTD. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP M8211G108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
1
Security
RGNT
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| GELLER EHUD | 23% | $8,730,279 | 1,332,867 | Dr. Ehud Geller | 31 Dec 2025 |
As of 30 Jun 2026, 6 institutional investors reported holding 845,791 shares of REGENTIS BIOMATERIALS LTD. - Ordinary Shares, no par value (RGNT). This represents 15% of the company’s total 5,745,116 outstanding shares.
13F concentration
Top 7 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
15%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Rosalind Advisors, Inc. | 12% | 701,685 | +179% | 0.93% | $2,476,948 |
| Warberg Asset Management LLC | 1.5% | 86,980 | 0.09% | $306,170 | |
| JANE STREET GROUP, LLC | 0.75% | 43,333 | 0% | $152,966 | |
| RENAISSANCE TECHNOLOGIES LLC | 0.23% | 13,348 | 0% | $47,118 | |
| UBS Group AG | 0.01% | 434 | +30% | 0% | $1,532 |
| Tower Research Capital LLC (TRC) | 0% | 11 | 0% | $39 | |
| AIGH Capital Management LLC | 0% | 0 | -100% | $0 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
3
Headline period
Q2 2026
Rows shown
1-3 of 3